Effect of Risperidone Combined with Sertraline on sTNFRs and Neuroelectrophysiological Characteristics in Schizophrenic Patients with Negative Symptoms
Abstract【Objective】To investigate the clinical effects of risperidone combined with sertraline in patients with schizophrenia-negative disease and its effects on soluble tumor necrosis factor receptor (sTNFRs) and neurophysiological characteristics.【Methods】The clinical data of 68 schizophrenic negative patients admitted to our hospital from May 2016 to November 2017 were analyzed retrospectively. They were divided into control group (risperidone) and observation group (risperidone combined with sertraline) according to different medication methods, 34 cases each. After 3 months of treatment, the negative symptoms, sTNFRs and electrophysiological characteristics of the two groups were compared.【Results】Three months after the treatment, the scores of emotional retardation, social disorder, personality isolation, frequent thinking and communication disorder in the observation group were lower than those in the control group, with statistical significance (P<0.05). The level of sTNFRs in the observation group was lower than that in the control group at 1, 2 and 3 months after treatment (P<0.05). After treatment, P300, N250 and ERN of the two groups were higher than before treatment, LPP amplitude was lower than before treatment; P300, N250 and ERN amplitude of the observation group were higher than that of the control group, LPP amplitude was lower than that of the control group, the difference was statistically significant (P<0.05).【Conclusion】Risperidone combined with sertraline in the treatment of negative schizophrenia can improve the symptoms, reduce the level of sTNFRs and improve the characteristics of neuroelectrophysiology, which is worth popularizing.
CHANG Xiao-juan,YANG Xiao-long,GAO Cheng-ge. Effect of Risperidone Combined with Sertraline on sTNFRs and Neuroelectrophysiological Characteristics in Schizophrenic Patients with Negative Symptoms[J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(1): 15-17.
[1] 张凤艳,钟慧,莫大明,等.青少年阴性与阳性症状精神分裂症患者的跨时决策比较研究[J].中华行为医学与脑科学杂志,2017,26(11):1009-1014. [2] 刘明秋.抗抑郁药文拉法辛对精神分裂症阴性症状、社会功能恢复的临床疗效研究[J].中国医院药学杂志,2016,36(6):484-487. [3] Nikbakhat M R, Arabzadeh S, Zeinoddini A, et al. Duloxetine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study[J]. Pharmacopsychiatry,2016,49(4):162-169. [4] 张琪.联合非精神药物治疗改善精神分裂症阴性症状的研究进展[J].中华精神科杂志,2017,50(3):231-234. [5] Németh G,Laszlovszky I,Czobor P,et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial[J]. Lancet,2017,389(10074):1103-1113. [6] 陈传刚,王静,尹晓煜,等.精神分裂症患者血清细胞因子水平变化及其与病情的关系[J].山东医药,2016,56(8):89-90. [7] 袁秀霞,朱琦玥,梁怀斌,等.首发未用药精神分裂症患者血清性激素与精神症状及认知功能的关系[J].中华医学杂志,2016,96(27):2155-2160. [8] 徐清,程灶火,刘晓伟,等.重复经颅磁刺激对慢性精神分裂症患者认知功能和血清脑源性神经营养因子水平的影响研究[J].中国全科医学,2017,20(25):3171-3177. [9] 马敬,岳凌峰,王宁,等.老年精神分裂症患者肺部感染游离氨基酸及一氧化氮与5羟色胺和总抗氧化能力的变化研究[J].中华医院感染学杂志,2016,26(12):2694-2696.
2020, Vol. 37 
